These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 28496142)
1. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Su TH; Shiau CW; Jao P; Yang NJ; Tai WT; Liu CJ; Tseng TC; Yang HC; Liu CH; Huang KW; Hu TC; Huang YJ; Wu YM; Chen LJ; Chen PJ; Chen DS; Chen KF; Kao JH Sci Rep; 2017 May; 7(1):1728. PubMed ID: 28496142 [TBL] [Abstract][Full Text] [Related]
2. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Su TH; Shiau CW; Jao P; Liu CH; Liu CJ; Tai WT; Jeng YM; Yang HC; Tseng TC; Huang HP; Cheng HR; Chen PJ; Chen KF; Kao JH; Chen DS Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7243-8. PubMed ID: 26039995 [TBL] [Abstract][Full Text] [Related]
3. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138 [TBL] [Abstract][Full Text] [Related]
4. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells. Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011 [TBL] [Abstract][Full Text] [Related]
5. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456 [TBL] [Abstract][Full Text] [Related]
6. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051 [TBL] [Abstract][Full Text] [Related]
7. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer. Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071 [TBL] [Abstract][Full Text] [Related]
8. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Liu CY; Tseng LM; Su JC; Chang KC; Chu PY; Tai WT; Shiau CW; Chen KF Breast Cancer Res; 2013; 15(4):R63. PubMed ID: 23938089 [TBL] [Abstract][Full Text] [Related]
9. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3. Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751 [TBL] [Abstract][Full Text] [Related]
10. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226 [TBL] [Abstract][Full Text] [Related]
11. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma. Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379 [TBL] [Abstract][Full Text] [Related]
13. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model. Tai WT; Shiau CW; Li YS; Chen YL; Chu PY; Huang JW; Hsu CY; Hsu YC; Chen PJ; Chen KF Mol Cancer Ther; 2014 Jan; 13(1):27-36. PubMed ID: 24275147 [TBL] [Abstract][Full Text] [Related]
14. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. Liu Y; Wang Z; Kwong SQ; Lui ELH; Friedman SL; Li FR; Lam RWC; Zhang GC; Zhang H; Ye T J Hepatol; 2011 Sep; 55(3):612-625. PubMed ID: 21251937 [TBL] [Abstract][Full Text] [Related]
16. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. Wang Y; Gao J; Zhang D; Zhang J; Ma J; Jiang H J Hepatol; 2010 Jul; 53(1):132-44. PubMed ID: 20447716 [TBL] [Abstract][Full Text] [Related]
19. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225 [TBL] [Abstract][Full Text] [Related]